Data / Form D filings / Lipocine Inc.
Lipocine Inc.: Form D filings
Lipocine Inc., a pharmaceuticals company in Salt Lake City, United States, filed 2 Form D notices with the SEC in 2013. The latest, on August 5, 2013, reports $38 million sold of a $38 million offering to 27 investors.
Find out what Lipocine Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 675 ARAPEEN DRIVE, SUITE 202, Salt Lake City, United States, 84108
- Phone
- (801) 994-7383
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2011
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1535955
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 5, 2013 | New notice | $38,019,984 | $38,019,984 | $0 | 27 | Jul 30, 2013 | sec.gov |
| Aug 5, 2013 | New notice | Indefinite | $0 | Indefinite | 100 | Jul 24, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mahesh V. Patel | Executive Officer, Director | |
| Gordhan K. Patel | Director | |
| Robert K. Merrell | Executive Officer | |
| John W. Higuchi | Director | |
| Srinivasan K. Venkateshwaran | Executive Officer | |
| William I. Higuchi | Director | |
| Gerald K. Simmons | Executive Officer |
Every Form D from the week of Aug 5, 2013 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Lipocine Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.